TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26289681

Group type: EXPERIMENTAL
Intervention: Cumulative opioid use (11 to 30 TSDs)
Number of subjects: 3434

Group type: EXPERIMENTAL
Intervention: Cumulative opioid use (31 to 90 TSDs)
Number of subjects: 3434

Group type: EXPERIMENTAL
Intervention: Cumulative opioid use (91 or more TSDs)
Number of subjects: 3434

Group type: EXPERIMENTAL
Intervention: Cumulative NSAID use
Number of subjects: 3434

Group type: EXPERIMENTAL
Intervention: Heaviest opioid use
Number of subjects: 3434

Group type: COMPARATOR
Intervention: Little or no opioid or NSAID use
Number of subjects: 3434
Study: 24123041

Group type: EXPERIMENTAL
Intervention: Docetaxel (60 mg/m²) plus carboplatin (AUC=6 mg/ml min)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Paclitaxel (200 mg/m²) plus carboplatin (AUC=6 mg/ml min)
Number of subjects: 90
Study: 21235340

Group type: EXPERIMENTAL
Intervention: Diamorphine treatment (12 months)
Number of subjects: 434

Group type: COMPARATOR
Intervention: Methadone treatment (12 months)
Number of subjects: 434
Study: 17980970

Group type: EXPERIMENTAL
Intervention: High-protease wound environment
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Low-protease wound environment
Number of subjects: 2
Study: 16514112

Group type: EXPERIMENTAL
Intervention: Three-times-weekly (TIW) regimen of clarithromycin, ethambutol, and rifampin
Number of subjects: 91
Study: 12399345

Group type: EXPERIMENTAL
Intervention: Computerised decision support system
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 60
Study: 10445622

Group type: EXPERIMENTAL
Intervention: 0.2 parts per million (ppm) O3 exposure
Number of subjects: 13

Group type: COMPARATOR
Intervention: Filtered air exposure
Number of subjects: 13
Study: 7546130

Group type: EXPERIMENTAL
Intervention: Polyol-containing saliva stimulants consumed voluntarily by residents of a VA Medical Center over a period of six to 30 months.
Number of subjects: 0
Study: 2310660

Group type: EXPERIMENTAL
Intervention: Sulindac (exact dosage and duration not specified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enalapril (control group)
Number of subjects: 0
Study: 426990

Group type: EXPERIMENTAL
Intervention: Etomidate 0.3 mg kg‐1
Number of subjects: 60

Group type: COMPARATOR
Intervention: Thiopentone 3.5 mg kg‐1
Number of subjects: 60
Study: 6196556

Group type: EXPERIMENTAL
Intervention: 600 mg prizidilol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30972875

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 5074

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 5074
Study: 29383550

Group type: EXPERIMENTAL
Intervention: Portal message promoting influenza vaccines
Number of subjects: 30000

Group type: EXPERIMENTAL
Intervention: IVR call promoting influenza vaccines
Number of subjects: 30000

Group type: EXPERIMENTAL
Intervention: Both portal message and IVR call
Number of subjects: 30000

Group type: COMPARATOR
Intervention: Usual care (control group) for portal users
Number of subjects: 30000

Group type: EXPERIMENTAL
Intervention: IVR call for non-portal users
Number of subjects: 30000

Group type: COMPARATOR
Intervention: Usual care for non-portal users
Number of subjects: 30000
Study: 26812861

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 25003289

Group type: EXPERIMENTAL
Intervention: Mitomycin-C arm of the Radiation Therapy Oncology Group 98-11 trial
Number of subjects: 121
Study: 22709754

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 1024

Group type: EXPERIMENTAL
Intervention: Bare metal stents (BMS)
Number of subjects: 1024

Group type: COMPARATOR
Intervention: Medical therapy (MED)
Number of subjects: 1024
Study: 20556560

Group type: EXPERIMENTAL
Intervention: Tapentadol prolonged release (PR; 100‐250 mg twice daily)
Number of subjects: 2968

Group type: COMPARATOR
Intervention: Oxycodone hydrochloride controlled release (CR; 20‐50 mg twice daily)
Number of subjects: 2968

Group type: EXPERIMENTAL
Intervention: Tapentadol PR
Number of subjects: 2968

Group type: COMPARATOR
Intervention: Oxycodone CR
Number of subjects: 2968
Study: 17670782

Group type: EXPERIMENTAL
Intervention: Automatic atrial overdrive (AO) pacing algorithm activated
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Automatic atrial overdrive (AO) pacing algorithm deactivated
Number of subjects: 277

Group type: COMPARATOR
Intervention: Control group (no PAF)
Number of subjects: 277
Study: 16245247

Group type: EXPERIMENTAL
Intervention: Medical therapy plus interventional percutaneous transluminal renal artery stenting (PTRS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 100
Study: 12400976

Group type: EXPERIMENTAL
Intervention: 160 mg/day of megestrol acetate
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: 320 mg/day of megestrol acetate
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: 160 mg/day and 320 mg/day of megestrol acetate
Number of subjects: 119
Study: 10446821

Group type: EXPERIMENTAL
Intervention: IVIG group (n = 19), received a commercially available human IgA- and IgM-enriched immunoglobulin preparation (dose, 20 g)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo group (n = 21), received physiologic saline
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (n = 20), patients with normal immune responses
Number of subjects: 40
Study: 7608311

Group type: EXPERIMENTAL
Intervention: Isradipine-CR 5 mg
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Isradipine-CR 10 mg
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Isradipine-CR 15 mg
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Isradipine-CR 20 mg
Number of subjects: 402

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 402
Study: 2114240

Group type: EXPERIMENTAL
Intervention: Oral glucose (100 g)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Supramaximal dose of GHRH (50 micrograms bolus, followed by 100 micrograms/h infusion for 3 h)
Number of subjects: 8
Study: 390336

Group type: EXPERIMENTAL
Intervention: Enteric-coated levodopa (Prodopa)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Levodopa-carbidopa combination (Sinemet)
Number of subjects: 27
Study: 31529024

Group type: EXPERIMENTAL
Intervention: Intensive antihypertensive treatment
Number of subjects: 9361

Group type: COMPARATOR
Intervention: Standard antihypertensive treatment
Number of subjects: 9361
Study: 31693918

Group type: EXPERIMENTAL
Intervention: CPP‐ACP sugar-free chewing gum
Number of subjects: 19

Group type: COMPARATOR
Intervention: No gum chewing
Number of subjects: 19
Study: 26884063

Group type: EXPERIMENTAL
Intervention: MemPics™ (experimental group)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group activities
Number of subjects: 94
Study: 25516380

Group type: EXPERIMENTAL
Intervention: Lamotrigine therapy
Number of subjects: 40
Study: 23413951

Group type: EXPERIMENTAL
Intervention: Liposomal paclitaxel combined with cisplatin (LP regimen)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Gemcitabine combined with cisplatin (GP regimen)
Number of subjects: 126
Study: 21216683

Group type: EXPERIMENTAL
Intervention: Erythropoiesis-stimulating agents (ESA) targeting a hemoglobin (Hb) level of 13 g/dL
Number of subjects: 4038

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4038

Group type: EXPERIMENTAL
Intervention: Erythropoiesis-stimulating agents (ESA)
Number of subjects: 4038
Study: 19474264

Group type: EXPERIMENTAL
Intervention: PsA‐TT conjugate vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meningococcal A/C polysaccharide vaccine (PsA/C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tetanus toxoid vaccine
Number of subjects: 0
Study: 17879675

Group type: EXPERIMENTAL
Intervention: Strips system
Number of subjects: 26

Group type: COMPARATOR
Intervention: Gel system
Number of subjects: 26
Study: 15487436

Group type: EXPERIMENTAL
Intervention: Unconscious control of semantic-level activation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conscious control of semantic-level activation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presence of a competitor and desired reward
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Absence of a competitor and desired reward
Number of subjects: 0
Study: 11991768

Group type: EXPERIMENTAL
Intervention: 20 g of ginseng root extract (GIN)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Water (control; CON)
Number of subjects: 8
Study: 9855767

Group type: EXPERIMENTAL
Intervention: Psychorelaxation therapy based on biological feedback
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (no psychorelaxation therapy)
Number of subjects: 43
Study: 7534777

Group type: EXPERIMENTAL
Intervention: Fluocinonide ointment plus prolonged occlusion
Number of subjects: 19

Group type: COMPARATOR
Intervention: Prolonged occlusion
Number of subjects: 19

Group type: COMPARATOR
Intervention: Fluocinonide ointment
Number of subjects: 19
Study: 2084586

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 36

Group type: COMPARATOR
Intervention: Diazepam and Fentanyl
Number of subjects: 36
Study: 37870

Group type: EXPERIMENTAL
Intervention: Nadolol (beta-blocker), given once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol (beta-blocker), given four times daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nadolol and Propranolol
Number of subjects: 0
Study: 31780346

Group type: EXPERIMENTAL
Intervention: CBT‐SE (8-session cognitive behaviour therapy group intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (only supported employment program)
Number of subjects: 0
Study: 30817739

Group type: EXPERIMENTAL
Intervention: Gadolinium enhancement of the disc herniation
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Gadolinium enhancement of the nerve root
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Degree of inflammation by macrophages
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Evaluation of patient groups with and without Modic type 2 changes
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Presence of Modic type 2 changes
Number of subjects: 119
Study: 29685828

Group type: EXPERIMENTAL
Intervention: 10°C Cold Water Immersion (CWI) for 10 minutes
Number of subjects: 33

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 33
Study: 26309227

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone during radiotherapy for 14 days
Number of subjects: 53

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 53
Study: 25709122

Group type: EXPERIMENTAL
Intervention: Continuous exercise training program (8 weeks, 60‐79% HR reserve, 45-60 minutes, 3 times per week)
Number of subjects: 357

Group type: COMPARATOR
Intervention: Control group (sedentary)
Number of subjects: 357
Study: 22436337

Group type: EXPERIMENTAL
Intervention: Manual interventions (e.g. manipulation, mobilization or soft tissue techniques)
Number of subjects: 38

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Follow-up sessions 2 and 3
Number of subjects: 38
Study: 18766426

Group type: EXPERIMENTAL
Intervention: Anakinra (1 mg/kg daily, ≤100 mg/day)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 17229548

Group type: EXPERIMENTAL
Intervention: Prophylaxis with single pre‐surgical dose of two tablets amoxicillin/clavulanate 1000/62.5 mg
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Pre‐emptive post‐surgery therapy with two tablets amoxicillin/clavulanate 1000/62.5 mg BID for 5 days
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Both prophylactic and therapeutic regimens
Number of subjects: 225
Study: 15172898

Group type: EXPERIMENTAL
Intervention: Omalizumab (n = 22)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo (n = 23)
Number of subjects: 45
Study: 11641547

Group type: EXPERIMENTAL
Intervention: SensiCath Blood Gas Monitoring System
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 44
Study: 9757201

Group type: EXPERIMENTAL
Intervention: Intravenous bolus injection of granisetron
Number of subjects: 38

Group type: COMPARATOR
Intervention: Intravenous drip infusion of granisetron over 30 minutes
Number of subjects: 38
Study: 7532991

Group type: EXPERIMENTAL
Intervention: Pamidronate 60 mg every 4 weeks
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Pamidronate 60 mg every 2 weeks
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Pamidronate 90 mg every 4 weeks
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Pamidronate 30 mg every 2 weeks
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Pamidronate (various regimens) in prostate cancer patients
Number of subjects: 119
Study: 3171001

Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 29722660

Group type: EXPERIMENTAL
Intervention: 74 Gy in 37 fractions (conventional fractionation)
Number of subjects: 3216

Group type: EXPERIMENTAL
Intervention: 60 Gy in 20 fractions (hypofractionation)
Number of subjects: 3216

Group type: EXPERIMENTAL
Intervention: 57 Gy in 19 fractions (hypofractionation)
Number of subjects: 3216

Group type: COMPARATOR
Intervention: Conventional fractionation (74 Gy)
Number of subjects: 3216

Group type: EXPERIMENTAL
Intervention: Hypofractionation (60 Gy)
Number of subjects: 3216

Group type: EXPERIMENTAL
Intervention: Hypofractionation (57 Gy)
Number of subjects: 3216

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiation therapy
Number of subjects: 3216

Group type: EXPERIMENTAL
Intervention: 57 Gy schedule
Number of subjects: 3216
Study: 28239017

Group type: EXPERIMENTAL
Intervention: Adapted evidence-based risk reduction program
Number of subjects: 251

Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 251
Study: 25425214

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study: 22961714

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil, folinic acid and oxaliplatin
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Hepatic arterial infusion of floxuridine with systemic irinotecan
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: (1) H MRS
Number of subjects: 34
Study: 20956486

Group type: EXPERIMENTAL
Intervention: Postconditioning (four cycles of 60 s reperfusion and 60 s of reocclusion before permanent reperfusion)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Standard percutaneous coronary intervention
Number of subjects: 76
Study: 18570226

Group type: EXPERIMENTAL
Intervention: 2.5 mg lorazepam (LZP)
Number of subjects: 23
Study: 16914475

Group type: EXPERIMENTAL
Intervention: One-piece acrylic IOL
Number of subjects: 100

Group type: COMPARATOR
Intervention: Three-piece acrylic IOL
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: One-piece acrylic IOL (combined vitrectomy)
Number of subjects: 100
Study: 14672266

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 8996762

Group type: EXPERIMENTAL
Intervention: Indefinite, high dose HBIG (10,000 mu or 40,000 mu/dose depending on HBV DNA status pretransplant)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Indefinite, high dose HBIG
Number of subjects: 17

Group type: COMPARATOR
Intervention: No immunoprophylaxis
Number of subjects: 17
Study: 8877207

Group type: EXPERIMENTAL
Intervention: Serous fluid
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: Mucoid fluid
Number of subjects: 222

Group type: COMPARATOR
Intervention: Both serous and mucoid groups
Number of subjects: 222
Study: 3532697

Group type: EXPERIMENTAL
Intervention: Metoprolol (15 mg i.v. + 50 mg orally q.i.d.)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 212
Study: 30486374

Group type: EXPERIMENTAL
Intervention: CPLE dentifrice
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CPLE dentifrice and mouthwash
Number of subjects: 100

Group type: COMPARATOR
Intervention: SLS-free enzyme-containing dentifrice
Number of subjects: 100

Group type: COMPARATOR
Intervention: SLS-free enzyme-containing dentifrice with essential oil mouthwash
Number of subjects: 100
Study: 27659881

Group type: EXPERIMENTAL
Intervention: Immediate coronary angiography (CAG) and percutaneous coronary intervention (PCI) within 2 hours
Number of subjects: 552

Group type: COMPARATOR
Intervention: Initial deferral with CAG and PCI after neurological recovery
Number of subjects: 552
Study: 25420455

Group type: EXPERIMENTAL
Intervention: MNP + Fe (2.5 mg iron as NaFeEDTA)
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: MNP + Fe
Number of subjects: 287

Group type: COMPARATOR
Intervention: MNP - Fe
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: MNP + Fe and MNP - Fe
Number of subjects: 287
Study: 23220254

Group type: EXPERIMENTAL
Intervention: Educational intervention (reading an educational guide and participating in an educational session)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 0
Study: 22352120

Group type: EXPERIMENTAL
Intervention: Metoprolol XL 50 mg + Amlodipine 5 mg
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Metoprolol XL 25 mg + Amlodipine 2.5 mg
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Metoprolol XL 50 mg
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Metoprolol XL 25 mg
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 402
Study: 18061407

Group type: EXPERIMENTAL
Intervention: Exposure to a deprived urban environment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Mindfulness relaxation task
Number of subjects: 30
Study: 16761467

Group type: EXPERIMENTAL
Intervention: Carotid angioplasty and stenting (CAS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 0
Study: 14700349

Group type: EXPERIMENTAL
Intervention: Culture
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: DFA test
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Both Culture and DFA
Number of subjects: 143
Study: 11105975

Group type: EXPERIMENTAL
Intervention: Unconstrained standing with mechanical loading, visual conditions, type of support surface, and sole of the shoes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statistical analysis of centre of pressure data
Number of subjects: 0
Study: 9370141

Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (45 mg beta-carotene, 825 mg alpha-tocopherol, and 450 mg ascorbic acid daily for three weeks)
Number of subjects: 26

Group type: COMPARATOR
Intervention: No antioxidant supplementation (BMT(-) group)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Healthy control group (N = 10) supplemented with the same doses as BMT(+)
Number of subjects: 26
Study: 1316400

Group type: COMPARATOR
Intervention: Candoxatril (single oral dose)
Number of subjects: 50

Group type: COMPARATOR
Intervention: High-sodium diet
Number of subjects: 50

Group type: COMPARATOR
Intervention: Low-sodium diet
Number of subjects: 50

Group type: COMPARATOR
Intervention: Crossover study design
Number of subjects: 50
Study: 3982016

Group type: EXPERIMENTAL
Intervention: FSCP-D (Femoral Systolic Pressures measured by compression technique using disappearance of the profunda femoris Doppler signal)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FSCP-P (Femoral Systolic Pressures measured by compression technique using flattening of thigh plethysmographic waveforms)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PTSP (Proximal Thigh Systolic Pressures)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FSCP-D (using soft bladder for arterial compression)
Number of subjects: 0
Study: 30020512

Group type: EXPERIMENTAL
Intervention: 12 week yoga-based lifestyle intervention (YBLI)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Dietary intervention (DI)
Number of subjects: 260
Study: 29397291

Group type: COMPARATOR
Intervention: Cervical plexus block alone (Group 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cervical plexus block + Mandibular block (Group 2)
Number of subjects: 0
Study: 26628419

Group type: EXPERIMENTAL
Intervention: Alogliptin
Number of subjects: 341
Study: 24658390

Group type: EXPERIMENTAL
Intervention: Telephone counseling
Number of subjects: 151

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 151
Study: 23111108

Group type: EXPERIMENTAL
Intervention: Internet‐administered cognitive behavior therapy (iCBT) for 9 weeks
Number of subjects: 96

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 96
Study: 20602280

Group type: EXPERIMENTAL
Intervention: Chlorhexidine oral gel
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 60
Study: 18008240

Group type: EXPERIMENTAL
Intervention: Single-dose sulfadoxine-pyrimethamine (SP)
Number of subjects: 387

Group type: COMPARATOR
Intervention: 2-dose sulfadoxine-pyrimethamine (SP)
Number of subjects: 387

Group type: COMPARATOR
Intervention: Monthly sulfadoxine-pyrimethamine (SP) IPT
Number of subjects: 387
Study: 15677374

Group type: EXPERIMENTAL
Intervention: Daily iron-folic acid (1 tablet/dose, 20 mg elemental iron and 0.1 mg folic acid/tablet)
Number of subjects: 803

Group type: EXPERIMENTAL
Intervention: Biweekly iron-folic acid (2 tablets/dose, 20 mg elemental iron and 0.1 mg folic acid/tablet)
Number of subjects: 803
Study: 11981066

Group type: EXPERIMENTAL
Intervention: cerivastatin 0.15 mg/day
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study: 10349966

Group type: COMPARATOR
Intervention: Occipital gamma and frontal beta induced activities during variable delay durations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (fixed short delay)
Number of subjects: 0
Study: 7594155

Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan (TCC)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Sedentary control
Number of subjects: 84
Study: 1428381

Group type: EXPERIMENTAL
Intervention: Actual acupuncture
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 36

Group type: COMPARATOR
Intervention: No stimulation (control group)
Number of subjects: 36